Description
Pacientes con mutación T790M o mutaciones sensibilizantes al EGFR
Alivia la indigestión
temblor o acatisia
PRINCIPIO ACTIVO: ERITROMICINA BASE
Emicizumab 150 mg/mL
E-400 CAP. FCO. C/30 PALMITATO DE Pacientes con mutación T790M oSUSTANCIA: E 400 CAP. FCO. C 30 FABRICANTE: GELCAPS
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
recommand products
